This is a four-year follow-up study for adolescent and adult males with Fragile X Syndrome who have already taken the investigational drug BPN14770 in earlier trials. The main goal is to check the long-term safety and side effects of the drug. Researchers will also track changes …
Phase: PHASE3 • Sponsor: Tetra Discovery Partners • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC